Navigation Links
DiaTech Oncology and Walter Reed Army Medical Center Establish Pilot to Determine Best Chemotherapy for Cancer Patients
Date:2/8/2011

WASHINGTON, Feb. 8, 2011 /PRNewswire/ -- DiaTech Oncology announced today they have engaged in a pilot with Walter Reed Army Medical Center to determine the best Chemotherapy for Cancer patients. Medical and GYN Oncologists and from Walter Reed have been working with DiaTech Oncology (Nashville, TN) using the MiCK assay for apoptosis in order to give physicians a tool that can predict the best chemotherapy pathway in treating cancer patients. The study will eventually be introduced to other military hospitals and results will be collected on multiple cancers. Previous studies published by DiaTech have demonstrated the MiCK assay can increase the patient's response to chemotherapy, resulting in increased patient survival. In addition, the assay can guide the physician on single vs. combination therapy and when generic vs. proprietary drugs are more effective.  

"To be able to predict the best chemotherapy treatment for cancer patients has been a goal for oncologists for many years and we now have the data that proves this technology works for all cancers. In addition the test can guide a physician on choosing between single drug or combination treatments and whether to use less expensive generic drugs or newer proprietary drugs based on which drugs will give the patient the most effective response," said Dr. Cary Presant, DiaTech Medical Director, and Professor of Clinical Medicine at the University of Southern California Keck School of Medicine.In the MiCK assay, the tumor cells of an individual patient are exposed to multiple doses of several chemotherapeutic drugs either as single drugs or in combinations. A sophisticated algorithm is used to monitor and compute the amounts of apoptosis caused by each of the drugs to establish a drug sensitivity profile of the patient's tumor cells. Knowledge of a patient's drug sensitivity profile allows the treating oncologists to prescribe chemotherapy that would be the most effective against the tumor cells of that patient.

No other technology in the market today can measure apoptotic cancer cell death directly and predict chemotherapy treatment. The capabilities and performance of the MiCK assay technology far exceed those of any other cancer testing assays available in the current market. It is the only test assay available today with proof-of-concept outcome data, utilizing 45 different chemotherapy agents and numerous combinations of drug therapy. The MiCK assay has been used successfully to test all types of cancers.

DiaTech Oncology is a privately held clinical pathology laboratory working to help oncologists and their patients deal with the devastating effects of cancer. DiaTech utilizes a patented technology called the Microculture Kinetic (MiCK) assay. The MiCK assay is the only test available that measures the chemotherapeutic drug effect for a specific patient kinetically and accurately.Contact:Steve Latimer1-866-556-5356http://www.diatech-oncology.com info@diatechoncology.com This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>

SOURCE DiaTech Oncology
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Genomic Health Announces Multiple Colon Cancer Studies at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
2. TELINTRA® Named One of the 10 Most Interesting Oncology Projects to Watch
3. Sentinel Oncology add ADME From O2h to Their New Extended Contract
4. US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials
5. US Oncology to Report 2010 Third Quarter Operating Results
6. Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology
7. Dr. Ramin Mirhashemi, MD of Gynecological Oncology Associates Discusses Uterine Fibroid Treatment with da Vinci Robotic Hysterectomy Surgery
8. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
9. Reportlinker Adds Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline
10. Reportlinker Adds Protein Kinase Therapeutics in Oncology - Where to Commercialize?
11. Reportlinker Adds Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Sequenom, Inc. (NASDAQ: SQNM ... lives through the development of innovative products and services, ... the United States denied its petition to ... of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") are ... by the Supreme Court,s Mayo Collaborative Services v. Prometheus ...
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and ... clinical trial team. , Using the CONSULT module, patients and physicians can schedule a ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... operations for Amgen, will join the faculty of the University of North ... adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
Breaking Biology Technology:
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
Breaking Biology News(10 mins):